News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
760,476 Results
Type
Article (51257)
Company Profile (346)
Press Release (708872)
Multimedia
Podcasts (119)
Webinars (17)
Section
Business (218704)
Career Advice (2582)
Deals (37786)
Drug Delivery (120)
Drug Development (85756)
Employer Resources (183)
FDA (17178)
Job Trends (16282)
News (369762)
Policy (35592)
Tag
Academia (2886)
Accelerated approval (10)
Adcomms (29)
Allergies (102)
Alliances (54351)
ALS (118)
Alzheimer's disease (1541)
Antibody-drug conjugate (ADC) (179)
Approvals (17146)
Artificial intelligence (358)
Autoimmune disease (35)
Automation (18)
Bankruptcy (386)
Best Places to Work (12316)
BIOSECURE Act (21)
Biosimilars (132)
Biotechnology (222)
Bladder cancer (99)
Brain cancer (38)
Breast cancer (383)
Cancer (3012)
Cardiovascular disease (236)
Career advice (2165)
Career pathing (34)
CAR-T (201)
CDC (36)
Cell therapy (541)
Cervical cancer (22)
Clinical research (70308)
Collaboration (1101)
Company closure (3)
Compensation (699)
Complete response letters (30)
COVID-19 (2852)
CRISPR (67)
C-suite (343)
Cystic fibrosis (120)
Data (3051)
Decentralized trials (2)
Denatured (44)
Depression (74)
Diabetes (364)
Diagnostics (6788)
Digital health (24)
Diversity (10)
Diversity, equity & inclusion (47)
Drug discovery (151)
Drug pricing (148)
Drug shortages (34)
Duchenne muscular dystrophy (129)
Earnings (91399)
Editorial (45)
Employer branding (22)
Employer resources (160)
Events (123436)
Executive appointments (895)
FDA (18878)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (986)
Gene editing (146)
Generative AI (30)
Gene therapy (418)
GLP-1 (892)
Government (4976)
Grass and pollen (5)
Guidances (181)
Healthcare (20219)
HIV (42)
Huntington's disease (31)
IgA nephropathy (43)
Immunology and inflammation (173)
Immuno-oncology (10)
Indications (40)
Infectious disease (3042)
Inflammatory bowel disease (159)
Inflation Reduction Act (13)
Influenza (68)
Intellectual property (124)
Interviews (448)
IPO (17267)
IRA (55)
Job creations (4380)
Job search strategy (1825)
Kidney cancer (13)
Labor market (52)
Layoffs (565)
Leadership (26)
Legal (8816)
Liver cancer (83)
Longevity (12)
Lung cancer (418)
Lymphoma (214)
Machine learning (11)
Management (63)
Manufacturing (427)
MASH (98)
Medical device (14172)
Medtech (14177)
Mergers & acquisitions (21235)
Metabolic disorders (933)
Multiple sclerosis (99)
NASH (21)
Neurodegenerative disease (137)
Neuropsychiatric disorders (41)
Neuroscience (2279)
NextGen: Class of 2025 (7155)
Non-profit (4920)
Now hiring (47)
Obesity (480)
Opinion (274)
Ovarian cancer (104)
Pain (120)
Pancreatic cancer (124)
Parkinson's disease (200)
Partnered (25)
Patents (312)
Patient recruitment (171)
Peanut (54)
People (61718)
Pharmaceutical (99)
Pharmacy benefit managers (25)
Phase I (21856)
Phase II (30883)
Phase III (23178)
Pipeline (1677)
Policy (231)
Postmarket research (2757)
Preclinical (9363)
Press Release (69)
Prostate cancer (145)
Psychedelics (42)
Radiopharmaceuticals (271)
Rare diseases (514)
Real estate (6653)
Recruiting (70)
Regulatory (24455)
Reports (51)
Research institute (2574)
Resumes & cover letters (417)
Rett syndrome (10)
RNA editing (10)
RSV (57)
Schizophrenia (97)
Series A (170)
Series B (117)
Service/supplier (13)
Sickle cell disease (65)
Special edition (20)
Spinal muscular atrophy (159)
Sponsored (36)
Startups (3986)
State (2)
Stomach cancer (16)
Supply chain (81)
Tariffs (63)
The Weekly (73)
Vaccines (890)
Venture capital (57)
Weight loss (314)
Women's health (50)
Worklife (20)
Date
Today (74)
Last 7 days (385)
Last 30 days (1980)
Last 365 days (32750)
2025 (17641)
2024 (36971)
2023 (41919)
2022 (53287)
2021 (57910)
2020 (56652)
2019 (49910)
2018 (37838)
2017 (34746)
2016 (34737)
2015 (40811)
2014 (34506)
2013 (29574)
2012 (31619)
2011 (32254)
2010 (30144)
Location
Africa (908)
Alabama (67)
Alaska (7)
Arizona (261)
Arkansas (14)
Asia (43744)
Australia (7124)
California (7622)
Canada (2399)
China (707)
Colorado (332)
Connecticut (332)
Delaware (200)
Europe (96881)
Florida (1143)
Georgia (254)
Hawaii (1)
Idaho (64)
Illinois (690)
India (29)
Indiana (377)
Iowa (17)
Japan (235)
Kansas (111)
Kentucky (32)
Louisiana (15)
Maine (73)
Maryland (1064)
Massachusetts (5789)
Michigan (262)
Minnesota (470)
Mississippi (3)
Missouri (99)
Montana (31)
Nebraska (26)
Nevada (81)
New Hampshire (70)
New Jersey (2142)
New Mexico (30)
New York (2150)
North Carolina (1191)
North Dakota (10)
Northern California (3331)
Ohio (245)
Oklahoma (17)
Oregon (40)
Pennsylvania (1637)
Puerto Rico (18)
Rhode Island (36)
South America (1301)
South Carolina (36)
South Dakota (1)
Southern California (2850)
Tennessee (129)
Texas (1154)
United States (28651)
Utah (227)
Virginia (202)
Washington D.C. (75)
Washington State (662)
West Virginia (4)
Wisconsin (83)
760,476 Results for "par pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is expanding its voluntary recall to include seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulates in the product.
April 22, 2024
·
5 min read
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level.
March 12, 2024
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners
June 16, 2025
·
6 min read
Press Releases
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
July 3, 2025
·
7 min read
Press Releases
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
June 26, 2025
·
4 min read
Press Releases
Universe Pharmaceuticals INC Announces Share Consolidation
March 20, 2025
·
3 min read
Press Releases
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 10, 2025
·
3 min read
Press Releases
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
June 26, 2025
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
April 21, 2025
·
4 min read
Press Releases
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
July 10, 2025
·
3 min read
1 of 76,048
Next
